减低剂量颅脊髓照射对标准风险成人髓母细胞瘤可行
INTRODUCTION: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults.…
要点
- 成人标准风险髓母细胞瘤采用23.4 Gy颅脊髓照射联合化疗,5年PFS达82.2±6.1%。
- 减低剂量组与儿童患者生存无显著差异,且高于23.4 Gy未改善PFS。
- 女性成人患者预后似优于男性。
核心结论
- 减低剂量颅脊髓照射联合化疗在标准风险成人髓母细胞瘤中可行,结果与高剂量照射相当或更优。
主要发现
- 成人中位随访101个月,5年PFS为82.2±6.1%、OS为89±5.2%,10年PFS为78.5±6.9%、OS为75.2±7.8%,与儿童无显著差异。
- 颅脊髓照射剂量高于23.4 Gy未影响PFS;女性成人患者结局趋向更好。
临床怎么用
- 对标准风险成人髓母细胞瘤,可考虑采用23.4 Gy颅脊髓照射联合化疗替代传统36 Gy方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. METHODS: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18-48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996-2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. RESULTS: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. CONCLUSION: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.
引用
- Massimino M, Sunyach MP, Barretta F, et al. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients. J Neurooncol. 2020. PMID: 32567042. doi:10.1007/s11060-020-03564-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。